NanoViricides’ SARS-CoronaVirus-2 Treatment Moving Towards Clinical Candidate Selection and IND Filing for COVID-19

Topical Drug Candidate Against Shingles (VZV) Preparing for Regulatory Trials;

An Array of Other Indications in Herpecide™ Program Alone

(Corporate Presentation
Presented at the LD Micro 500 Virtual Investor Conference on September 3, 2020)

Presented by:
Anil R. Diwan, PhD
President & Exec. Chairman
Mobile: 203-606-9180
adiwan@nanoviricides.com
NanoViricides, Inc. is a NYSE-American listed publicly traded company (stock symbol: NNVC). This is not an offering memorandum and should not be construed as such. It is provided as a non-confidential document for informational purposes only.

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials as therapeutics against a number of different viruses. The Company’s novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. All of our drug candidates are based on broad and exclusive worldwide licenses in perpetuity from TheraCour Pharma, Inc. for the development of drugs to combat viral infections of Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Viruses (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu viruses, Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis virus, viruses causing viral Conjunctivitis (a disease of the eye). The Company has executed a Memorandum of Understanding with TheraCour that provides a limited license for research and development for drugs against human coronaviruses. The Company intends to obtain a full license and has begun the process for the same. The Company’s technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

This document contains forward-looking statements that reflect the current expectation of NanoViricides, Inc. (the “Company”) regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements.

The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.

Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
Presentation Layout

- SARS-CoV-2 Therapeutics Development Strategy and Status
- Lead Drug Candidate Emerging Against SARS-CoV-2
- NV-HHV-101 for Shingles Rash Indication - IND prioritized after SARS-CoV-2
- Developing Drugs that Virus May Not Escape due to Mutations
- Industry-Leading Platform Technology Exclusively Licensed from TheraCour Pharma, Inc.
- Our Own cGMP-Capable Manufacturing, R&D, and Nanomedicine Characterization Facility Enables Rapid Development and Potential for Early Commercialization Revenues On Our Own
- Broad Pipeline with Multi-Billion Dollar Markets
- Current Focus on CoronaVirus Program (COVID-19)
- HerpeCide™ Program with a Franchise of Drugs
- NV-HHV-101 - Shingles Rash - Drug Candidate
- Technology Strategy, Other Programs
- Team
SARS-CoV-2 has caused the COVID-19 pandemic which is costing economies several trillions of dollars and several hundreds of thousands of lives.

We are developing a drug mimicking ACE2, the receptor that SARS-CoV-2 binds to.

Mutations in SARS-CoV-2 are already known, vaccines and antibody drugs are anticipated to fail by scientists.

Mutants would not be able to escape our drug.

We have cGMP manufacturing capability to produce several hundreds to thousands of treatments per batch.
By April, 2020, We had already:

- Found Small Chemical Ligands Using Molecular Modeling that Bind to SARS-CoV- Spike Protein at Its ACE2-Receptor Interface
- Produced Certain Ligands at 50g to Kg Scales Already
- Polymer is Already at Multi-Kilogram Scale - cGMP-Like
- Produced Nanoviricide Drug Candidates Against SARS-CoV-2
- Developed Anti-Coronavirus Effectiveness Test in Cell Culture Using Model Coronaviruses
- Broad-spectrum Effectiveness Would Strongly Indicate Mutations should not cause loss of drug effect
By July, 2020, We had already:

- Developed a BSL2 Animal Model of ACE2-utilizing h-CoV-NL63 Coronavirus for
- This Surrogate for BSL3/4 SARS-CoV-2 is now believed to provide people with protection against SARS-CoV-2 (one of the common-cold viruses)
- Animal Model Effectiveness of NanoViricides Drug Candidates Established - Setting Stage for Clinical Candidate Selection
- NanoViricides Candidates found to be Superior to Remdesivir in that Animal Model Study
- Safety of Coronavirus Drug Candidates Established in a non-GLP Animal Model Study - Setting Stage for GLP Studies required for an IND
By September, 2020, We are already:

- Close to Declaring a Clinical Candidate, named NV-CoV-1
- Awaiting Data Analysis of Cell Cultures Studies in Our Own BSL2 Virology Lab - Data looks exciting, will publicize soon
- Awaiting Completion of Animal Efficacy Study (hCoV-NL63 as surrogate) for Clinical Candidate Selection
- Working on Drafting a Pre-IND Application to the US FDA
- Working on Starting Safety Pharmacology Studies for IND
- CMC Section of a Potential IND is Almost Completed
- Working on Discussions with CRO’s for Clinical Trials
Novel Platform Technology: A nanoviricide® is a Cell Mimic

Viral Resistance to the Nanoviricide Drug is Unlikely because Even as the Virus Mutates, It Still Binds to the Same Cell Surface Receptor(s), in the Same Fashion

A nanoviricide “Looks Like” a Human Cell to the Virus

A nanoviricide is large enough for a virus particle to latch onto it. Yet small enough to circulate readily in the body.

Rather than the virus particle entering into a nanoviricide, a nanoviricide wraps around the virus particle and encapsulates it, by using the virus particle’s very same ability to enter a cell.

© All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE-mkt: NNVC)
SARS-Cov-2 NanoViricide Drug Mechanism is Orthogonal to Most Other Drug Candidates

- Putative Mechanism of Action of a NanoViricides Drug Candidate is by Direct and Targeted Attack on the Virus Particle
- Blocks Virus Reinfection Cycle
- Potentially the NanoViricide Drug Can Bind to Infected Cells Because They Also Have S-Protein on the Surface - Sparing Uninfected Cells that Do Not
- Combining This Action with that of Replication Cycle Inhibitors Should Provide Full Control of the Virus Infection
- Further, NanoViricide Drug Itself Can Act as Delivery and Protector Vehicle for Such Small Chemical Drugs
- Encapsulation Into NanoViricide - Next Generation of NanoViricides Drugs
- Remdesivir (RDV) Has Emergency Use Approval
- RDV Works Great in Cell Culture Studies, But Clinical Results are Poor, Because of Rapid Metabolism
- Encapsulation of RDV into NV-CoV-1 May Overcome This Issue As well
- Studies Initiated Already
A NanoViricide® Attacking a Virus Particle: Unique, Novel, Nanotech Design

Attacking the Virus Using Its Own, Conserved, Cell-Binding Features: Multi-point, Multi-targeted Therapeutics

1. A nanoviricide® binds to a virus particle
2. Bound nanoviricide® lipid fusion with virus particle
3. Bound nanoviricide® wrapping onto virus particle
4. A virus particle destroyed by a nanoviricide®
Healthy Financial Position

- Reported $6.44 Million (M) Cash at end of March 30, 2020 Quarter
- Subsequent Two Raises (No Warrants Issued), Added about $19.8M
- Last Raise at $7.30/share
- Burn Rate is About $1.6 Million per Quarter
- Have Sufficient Funds to Support Anticipated Clinical Trials of At Least One Drug Through Phase 1/2
- Market Cap Hit Badly in 2017 through 2019 (declining cash reserves, and a reverse split) - Currently ~$57M
- Comparables are at several hundreds to few billions of dollars in market cap
Lead Drug Candidate NV-HHV-101 Skin Cream for Treatment of Shingles Rash: Business Case

- Potentially Billion+ Dollar Market for Topical Shingles Rash Treatment alone, even after the new vaccine Shingrix® has been introduced
  - 500,000 to 1,000,000 Cases Annually in the USA Alone

- Additionally, NV-HHV-101 is Expected to Lead into Dermal Topical Treatments for:
  - HSV-1 “Cold Sores”, and
  - HSV-2 “Genital Ulcers”

- Open Multi-Billion Dollar Additional Markets

- Many Additional Indications

- Expanding Indications means Improving ROI and Maximizing Shareholder Returns
All Required IND-Enabling Studies are Completed

cGMP Manufacture for GLP Safety/Toxicology Studies Completed

Almost All Reports are In Hand

Regulatory Consultants Retained

IND Drafts are Being Circulated

Clinical Trials Sites in Talks to Establish Agreements

Clinical Trial Design Consultants Retained

Clinical Trial Proforma Design Almost Ready

Phase 1/2 Adaptive Clinical Trial Protocol Being Drafted
Nanoviricides Dismantling MCMV Virus Particle

<table>
<thead>
<tr>
<th>Control</th>
<th>Treated</th>
</tr>
</thead>
</table>

**MCMV Virus Particle Containing Multiple Capsids**

*Virus Dismantled; Capsids Spilling Out*

**A**: intermediate state; **C**: total dismantling
NanoViricides is a Unique Drug Developer Company with Its Own cGMP-Capable Manufacturing Capability

Clinical Product Supply Capability for Mostly All of Our Nanoviricides

Significant Time and Cost Savings

Potential for Manufacturing Commercial Product - Market Entry & Early Revenues

Nanomedicines Characterization Facility

Virology BSL-2 Certified Lab

Protect Proprietary Technology & Intellectual Property

Rapid Transfer from Lab Bench to cGMP Manufacture

Highly Customizable and Flexible Pharma Manufacturing Capability

Skin Creams, Eye Drops, Gels, Injectables, Oral…
NanoViricides Platform Technology Has Enabled Several Drug Programs for a Broad Drug Pipeline

Pre-Clinical Successes Achieved in Several Programs

<table>
<thead>
<tr>
<th>FluCide™ Injectable</th>
<th>FluCide™ Oral</th>
<th>HIVCide™</th>
<th>DengueCide™</th>
<th>Other Programs: Platform Technology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potentially One Drug for All Influenzas</td>
<td>Potentially One Drug for All Influenzas</td>
<td>Potentially “Functional Cure”</td>
<td>Avoid ADE Effect</td>
<td>Select Ligand for Different Virus</td>
</tr>
<tr>
<td>Injectable for High Potency</td>
<td>Oral for Ease of Use by Out-Patients</td>
<td>Possibly the Only Technology Platform that Can Enable Total Cure of HIV by Hunting Out Latent Infection</td>
<td>NanoViricides has Orphan Drug Benefits in US &amp; EU</td>
<td>Select Polymer Backbone for Desired Route of Administration</td>
</tr>
</tbody>
</table>

Many More Possibilities for the Platform

The overall anti-viral market addressed by our programs was estimated to be $40 billion in 2018 and $65.5 billion in 2023


© All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE-Amer.: NNVC)
Our Current Focus is on the HerpeCide™ Program Regulatory Development

NanoViricides Leveraging HerpeCide Program Developments into Multiple Drugs Franchise

<table>
<thead>
<tr>
<th>VZV Shingles</th>
<th>HSV-2 Genital Lesions</th>
<th>HSV-1 Cold Sores</th>
<th>Herpes Keratitis</th>
<th>“ARN” Acute Retinal Necrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lead Drug Candidate NV-HHV-101</strong></td>
<td>HSV-2</td>
<td>HSV-1</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Shingles Rash Treatment</strong></td>
<td>Genital Ulcers Treatment</td>
<td>Cold Sores Treatment</td>
<td>Herpes Keratitis Treatment</td>
<td>Acute Retinal Necrosis Treatment</td>
</tr>
<tr>
<td><strong>IND-Enabling Studies; Pre-Clinical</strong></td>
<td>Pre-Clinical Optimization</td>
<td>Pre-Clinical Optimization</td>
<td>Pre-Clinical</td>
<td>Pre-Clinical</td>
</tr>
<tr>
<td><strong>Dermal Topical Skin Cream</strong></td>
<td>Dermal Topical Skin Cream</td>
<td>Dermal Topical Skin Cream</td>
<td>Eye Drops</td>
<td>Injectable</td>
</tr>
</tbody>
</table>

Additional Future Indications in HerpeCide Program

- Chickenpox (Possibly Orphan Drugs)
- PHN (Post-Herpetic Neuralgia)
- Recurrent Herpes Labialis

Market Size for HerpeCide™ Program Drugs estimated at Over $3-$5 Billion Lead Indication Shingles Rash Market Size estimated at $1 Billion or More (takes into account impact of Shingrix and other Vaccines)

© All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE-Amer.: NNVC)
NanoViricides’ Regulatory Strategy

Dermal Topical Drug as First Candidate -> Quicker Path

rather than systemic therapeutics

Multiple Indications with Same Drug Candidate or its Derivatives to Maximize Shareholder Value and ROI

VZV Shingles
HSV-2 Genital Herpes
HSV-1 Herpes Labialis “Cold Sores”

Herpes Keratitis (HSV-1 >95%) (External Eye)
Also: Ocular Herpes; Acute Retinal Necrosis; Other Indications
Lead Drug Candidate NV-HHV-101 Status - Getting Ready for IND Filing

Indication: Shingles Rash Treatment. Form: Topical Skin Cream

Anticipate Human Clinical Trials to Begin in CY 2020 Q1/Q2

FDA Response “Generally Adequate” on Pre-IND Filed with FDA

Non-Clinical Safety/Toxicology Studies Complete - except certain analyses

Awaiting GLP Safety/Toxicology Study Reports

External Collaborations for IND Write-ups, Clinical Trial Design, eCTD Conversion, and FDA Submission in Progress

Clinical Trial Site Selection in Progress

Proposed Adaptive Protocol Phase I Plus Phase IIa Combined

IND Filing - Major Milestone

Program Expected to Provide Value-Driving Data Reads As the Trials Progress
Investment Thesis:
NanoViricides Platform Technology and Facility

Platform Technology - A “Venus-Fly-Trap” for Viruses - “Bind-Encapsulate-Destroy” - Drugs that Viruses Cannot Escape by Mutations

Multiple Drug Programs with Many Candidates having demonstrated Successful Animal Model Effectiveness and Safety

Enable Continuing Future Growth

Own cGMP Manufacturing Facility Supplying Clinical Product Needs

- Saves Money, Time, and Minimizes IP Exposure
- May Enable Production for Early Commercial Market Entry

Early Successes - Strong Effectiveness in Influenza, HIV

Now Focused on Regulatory Development of Drugs in HerpeCide™ Program

IND-Enabling Safety and Effectiveness of First Drug Candidate Demonstrated

Validate Platform Substantially as First Drug Goes Through Clinical Trials
Company Founded and taken public (reverse shell merger) in 2005 - Platform Technologies Licensed from TheraCour Pharma, Inc.

Market Cap Historically Around $100~150M

Uplisted to NYSE-American in September 2013

Moved to Integrated cGMP Manufacturing & R&D Facility in 2015

Fully Owned Facility Asset Value ~$10M Net-of-Depreciation

Focused on Regulatory Development of HerpeCide Program

“Valley of Death” Phenomenon

Valuation May be Anticipated to Go Substantially Higher with First Drug Entering Clinical Trials

Large Market Sizes Enable Strong Future Potential
Shingles Rash breakouts - HHV-3 aka VZV

Unmet Medical Need: Available drugs in use not very effective (vaccines exist)

The chickenpox virus surviving in ganglia causes Shingles in adults

- About 500,000 to 1 Million Cases Per Year in the USA Alone
- Risk Increases with Age

Triggered by Reduced Immune Function

- Stress, Age, Immune Compromised/Suppressed

Severe Stinging Pain & Zosteriform Rash

- Pain May Persist for Months or Years After Resolution of Outbreak - PHN
- Virus Damaged Nerves Continue to Signal Sharp, Debilitating Pain
- Pain Could be Avoided/Minimized if Virus is Controlled

Broad-Spectrum HerpeCide™ Could be a Highly Effective Drug

Potential Billion+ Dollar Market Size projected even after the new vaccine introduction
Lead Drug Candidate NV-HHV-101
Dermal Topical Skin Cream for Treating Shingles Rash

Risk is Minimized for Human Clinical Studies,
Since Efficacy and Safety Data are Obtained in Human Skin Itself

Standard of Care, Valtrex® Oral, is Not Very Effective

Because viral TK enzyme activity required for converting Acyclovir class of drugs to active form is very poor in VZV compared to HSV-1 or HSV-2

5x More Effective than Acyclovir in Cell Culture

Human Skin Patch Organ Culture Studies ->

Highly Effective

Very Safe - No Histological Changes

Studies in Professor Jennifer Moffat Lab, Upstate Medical Center, SUNY, Syracuse, NY

Professor Moffat is a Leading Researcher in VZV Infection
Optimization Studies
VZV (Shingles) Topical Candidates Highly Effective - Five Times More Effective against VZV than Acyclovir in Cell Cultures (Pre-Clinical)

Also, Against HSV-1 and HSV-2, Found Similar Strong Effectiveness in Cell Cultures using multiple virus strains and multiple cell lines

Poster Presented by NanoViricides at the American Society of Virology Annual Meeting, 2018, Madison, WI.
VZV (Shingles) Topical Drug Candidates Are Highly Effective Match Efficacy of Cidofovir in Human Skin Organ Culture Model of VZV Infection (Pre-Clinical)

Note: Cidofovir is highly toxic (https://reference.medscape.com/drug/vistide-cidofovir-342606#5)
VZV (Shingles) Topical Candidate Moving Rapidly To Clinical Trials

Preliminary Non-GLP Safety/Tolerability Studies in Rats Successful (2018)

- No clinically observable adverse safety and toxicology effects in topical administration
- No clinically observable adverse safety and toxicology effects in systemic administration (IV or IP)
- No observable direct effects on the primary organ functions whether the drug was administered to the skin or systemically
  - Liver and kidney function is unaffected, among other organs
- Consistent with Strong Safety Observed in Human Skin Patch Efficacy Model Studies

Thereupon Undertook Manufacturing Scale-up, Final Drug Candidate Optimization, Final Drug Product Formulation, and Entry into IND-enabling Safety/Toxicology Studies (“Tox Package”)
VZV (Shingles) Topical Drug Candidate: IND-Enabling Safety/Toxicology Package Studies
Non-GLP Studies

Non-GLP Portion of IND-Enabling Safety/Toxicology Studies Completed by BASi, IN ca. February, 2019

Excellent Safety Profile Observed

cGMP Manufacture for GLP Safety/Toxicology Studies Completed

GLP Studies began in May, 2019, at BASi, IN

**GLP Safety/Toxicology Studies**

In-life Portion of GLP Studies completed in July 2019, at BASi, IN

Excellent Safety Profile Observed in Clinical Observations

Toxicokinetics Studies In Progress - Almost Complete

Histological Studies Complete

Awaiting Reports
HerpeCide™ Program Future Expansion

Drug Candidates in Current HerpeCide Program

May Have Applications Against Other HerpesViruses:

- Epstein-Barr Virus:
  - Mononucleosis
  - Monoclonal Gammopathy
  - other B-cell diseases, etc.

- Cytomegalovirus: Retinitis, Organ Transplant etc.

- HHV-6A, HHV-6B, HHV-7
  - several diseases are associated
  - encephalopathy, epilepsy
  - sialoadenopathy, Sicca syndrome
  - T-cell diseases
Strong Executive Team

Anil R. Diwan, PhD
President & Exec. Chairman

- Co-Founder
- Led Uplisting to NYSE-American Exchange in 2013
- Raised $65M
- Co-Inventor of Nanoviricides® & of TheraCour®
- 25+ years Leadership & Entrepreneurial experience
- Key Patents, Several NIH SBIR Awards
- PhD (Biochem Eng - Rice), BTech (ChemEng - IITB)

Randall W. Barton, PhD
CSO and Acting CRO

- 30+ Years of Pharmaceutical Industry Experience in Drug Discovery and Pre-clinical Regulatory Development
- Former Director of In-Vitro Cardiovascular Research at Boehringer Ingelheim
- Nevirapine (Viramune™) Development
- Visiting Faculty at the University of Connecticut Medical School, Farmington, CT

Meeta R. Vyas, MBA
CFO

- 30+ years Experience in Corporate Performance Improvement, Finance, M&A, EBITDA Growth...
- Previously: Principal, The Gores Group; Director, Kamylon Capital; CEO, Signature Brands, Inc. (a public company, known for “Mr. Coffee”); Ran $1B GE Appliances Division; Consultant, McKinsey & Company
- MBA (Fin.) Columbia, BS (ChemEng) MIT

Jayant Tatake, PhD
VP, R&D

- 30+ Years of Pharmaceutical Industry Experience in Drug Discovery, Manufacturing, QA/QC, CRO
- Synthesis, Scale-up, Formulations, and Pharmaceutical cGMP Expertise
- Former Asst. Director, Pharma. Analytics, InterPharm, Inc.
- Co-Inventor of Nanoviricides® & TheraCour®
- PhD UICT, Bombay
Board of Directors

Anil R. Diwan, PhD
President & Exec. Chairman
Co-Founder, Led Uplisting to NYSE-Amer. in 2013, Raised $65M+, Co-Inventor of Nanoviricides® & of TheraCour ®
25+ years Leadership & Entrepreneurial experience

Not an Independent Board Member
Director and Chairman Since Founding in 2005

Stanley Glick, CPA ✔
Chairman, Audit Committee
Auditing, Accounting, Tax, & Mgmt. Advisory Services
Financial Management Oversight, Civic Leader

Independent Board Member and Chair of Audit Committee since June 2012

Mak Jawadekar, PhD ✔
35+ Years of Pharmaceutical Industry Experience, Pharma Strategic Consultant. Previously at Pfizer, Inc., as Director, Portfolio Management & Analytics, and as Vice President, Asia Colleague Resource Group, in Pfizer Global R&D. Business and Research experience in joint ventures, alliance management, contracting, pharma R&D, drug delivery, clinical supply manufacture, etc. Global experience working with United States, Europe, India, Japan, China.

Independent Board Member since February, 2020

Hon’ble Theodore “Todd” Rokita, JD ✔
Former US Rep. from Indiana (4 terms since 2010). Served on several House Committees. Co-owner, General Counsel and Vice President of External Affairs, Apex Benefits Group, Inc. Extensive executive, team-building, business strategy, and fiscal management expertise in the private sector, alongside his public service leadership experience. Serves or has served as a Member of the Board of Directors of several commercial and charitable institutions.

Independent Board Member since May, 2020

✔ = Independent Board Member
Recap

“Resistance is Futile” - Antiviral Nanomachines Designed to Destroy Viruses Despite Viral Mutations

Broad and Deep Pipeline based on Platform Technology

Next Generation NanoViricides (with Encapsulated Additional Action) Already in Development

In-house cGMP Manufacture Enabling Early Commercial Revenues On Its Own

Major Regulatory Progress and Milestones to Occur Throughout Next Several Years

Starting with Upcoming IND for NV-HHV-101 Shingles Rash

Human Skin Pre-clinical Studies De-risk Clinical Development

Strong Asset Position

Expert team

Valuation
The End